

# Major R&D Pipeline: 5DXd-ADCs

| Phase 1   |   | Phase 2   |   | Phase 3   |  |
|---|---|---|---|---|--|
| (US/EU/Asia) HER2+ BC 2L+/1L<br>DESTINY-Breast07                              | (JP/US) solid tumors<br>TROPION-PanTumor01  | (US/EU/Asia) TNBC<br>(durvalumab combo)<br>BEGONIA          | (JP/US/EU/Asia) solid tumors<br>TROPION-PanTumor03  | (JP/US/EU/Asia) HER2+ BC<br>adjuvant* <sup>1</sup><br>DESTINY-Breast05                        |  |
| (US/EU/Asia) HER2 low BC<br>Chemo naïve/ post chemo<br>DESTINY-Breast08       | (CN) NSCLC, TNBC<br>TROPION-PanTumor02  | (CN) HER2+ GC 3L<br>DESTINY-Gastric06                       | (JP/US/EU/Asia) NSCLC (w/ AGA)<br>TROPION-Lung05  | (JP/US/EU/Asia) HER2 low BC<br>chemo naïve<br>DESTINY-Breast06                                |  |
| (JP/US/EU/Asia) HER2+ GC combo, 2L+/1L<br>DESTINY-Gastric03                   | (JP/US/EU/Asia) NSCLC (w/o AGA,<br>pembrolizumab combo)<br>TROPION-Lung02               | (CN) HER2 mutant NSCLC 2L+<br>DESTINY-Lung05                | (US/EU/Asia) TNBC<br>(durvalumab combo)<br>BEGONIA  | (JP/US/EU/Asia) HER2+ BC 1L<br>DESTINY-Breast09   |  |
| (US/EU/Asia) HER2+ NSCLC<br>(durvalumab, MEDI5752 combo) 1L<br>DESTINY-Lung03 | (JP/US/EU) NSCLC (w/o AGA,<br>durvalumab, AZD2936 and MEDI5752<br>combo) TROPION-Lung04 | (US/EU/Asia) NSCLC<br>(durvalumab combo) 2L+<br>HUDSON      | (JP/US/EU/Asia) EGFR mutated<br>NSCLC (osimertinib combo) 2L<br>ORCHARD                   | (JP/US/EU/Asia) HER2+ BC<br>neoadjuvant<br>DESTINY-Breast11                                   |  |
| (US/EU) BC, bladder<br>(nivolumab combo)                                      | (JP/US/EU/Asia) solid tumors<br>(AZD5305 combo)<br>PETRA                                | (JP/US/EU/Asia) HER2+ CRC 3L<br>DESTINY-CRC02               | (US/EU/Asia) resectable early-stage<br>NSCLC (durvalumab combo) neoadjuvant<br>NeoCOAST-2 | (US/EU/Asia) HER2 low BC,<br>HER2 IHC 0 BC, 2/3L<br>DESTINY-Breast15                          |  |
| (US/EU) BC, NSCLC<br>(pembrolizumab combo)                                    | (JP/US/EU/Asia) NSCLC   | (JP/US/EU/Asia)<br>HER2 mutant tumor<br>DESTINY-PanTumor01  | (JP/US/EU/Asia) EGFR mutated<br>NSCLC 3L<br>HERTHENA-Lung01                               | (JP/EU/Asia) HER2+ GC 2L<br>DESTINY-Gastric04   |  |
| (US/EU/Asia) solid tumors<br>(AZD5305 combo)<br>PETRA                         | (JP/US) EGFR mutated NSCLC<br>(osimertinib combo)                                       | (US/EU/Asia)<br>HER2 expressing tumor<br>DESTINY-PanTumor02 | DS-7300 (JP/US/EU/Asia)<br>ES-SCLC  | (JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or<br>exon 20 mutation) 1L<br>DESTINY-Lung04           |  |
| DS-7300 (JP/US)<br>ESCC, CRPC, squamous NSCLC, SCLC, etc.                     | (JP/US/Asia) HER3+ BC   |   |   | (JP/US/EU/Asia) NSCLC 2/3L<br>TROPION-Lung01  |  |
| DS-6000 (JP/US)<br>Renal cell carcinoma, ovarian cancer                       |   |   |   | (JP/US/EU/Asia) non-squamous NSCLC (w/o<br>AGA, pembrolizumab combo) 1L<br>TROPION-Lung07     |  |
|   |   |   |   | (JP/US/EU/Asia) NSCLC (w/o AGA,<br>pembrolizumab combo) 1L<br>TROPION-Lung08                  |  |
|   |   |   |   | (JP/US/EU/Asia) BC* <sup>2</sup> 2/3L<br>TROPION-Breast01                                     |  |
|   |   |   |   | (JP/US/EU/Asia) TNBC (PD-1/PD-L1 inhibitor<br>ineligible) 1L<br>TROPION-Breast02              |  |
|   |   |   |   | (JP/US/EU/Asia) TNBC (mono or<br>durvalumab combo) adjuvant* <sup>3</sup><br>TROPION-Breast03 |  |
|   |   |   |   | (JP/US/EU/Asia) EGFR mutated<br>NSCLC 2L<br>HERTHENA-Lung02                                   |  |

- T-DXd
- Dato-DXd
- HER3-DXd
- DS-7300 (I-DXd)
- DS-6000 (R-DXd)
- Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
- Breakthrough Designation (US)
- Orphan drug designation (designated in at least one country/region among JP, US and EU)

\* 1 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy  
 \* 2 HR+, HER2 low or negative BC  
 \* 3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy  
 AGA: actionable genomic alterations, BC: breast cancer, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

# Major R&D Pipeline: Next Wave

| Phase 1  |  | Phase 2   |  | Phase 3   |  | Filed  |  |
|--|--|---|--|---|--|--|--|
| DS-1055 (JP/US)<br>Anti-GARP antibody<br>Solid tumors  | DS-7011 (US)<br>Anti-TLR7 antibody<br>Systemic lupus erythematosus | Valemetostat (DS-3201)(JP/US/EU/Asia)<br>EZH1/2 inhibitor<br>PTCL |  | Pexidartinib (JP/Asia)<br>CSF-1/KIT/FLT3 inhibitor<br>Tenosynovial giant cell tumor                             |  | Quizartinib (EU)<br>FLT3 inhibitor<br>AML 1L   |  |
| DS-1594 (US)<br>Menin-MLL binding inhibitor<br>AML, ALL  | DS-2325 (EU) in prep<br>KLK5 inhibitor<br>Netherton syndrome       | Valemetostat (DS-3201) (EU)<br>EZH1/2 inhibitor<br>BCL            |  | Esaxerenone (JP)<br>MR blocker<br>Diabetic nephropathy  |  | Mirogabalin (CN)<br>α2δ ligands<br>Diabetic peripheral neuropathic pain  |  |
| DS-9606 (US/EU)<br>Target undisclosed ADC<br>Solid tumors  |  | DS-1001 (JP)<br>Mutant IDH1 inhibitor<br>Glioma                   |  | VN-0102/JVC-001 (JP)<br>Measles mumps rubella combined vaccine  |  | DS-5670 (JP)<br>COVID-19 mRNA vaccine (mutant strain)<br>COVID-19 (booster vaccination, 12 years old and over) |  |
| DS-1103<br>Anti-SIRPα antibody<br>HER2 expressing or mutant advanced metastatic solid tumors, HER2 low BC (ENHERTU® combo) |  | DS-1211 (US/EU)<br>TNAP inhibitor<br>Pseudoxanthoma elasticum     |  | DS-5670 (JP)<br>COVID-19 mRNA vaccine (original strain), COVID-19 (primary vaccination, 12 to 17 aged children) |  |  |  |
| DS-3939<br>Anti-TA-MUC1 ADC<br>Solid tumors  |  | VN-0200 (JP)<br>RS virus vaccine<br>RS virus infection            |  | DS-5670 (JP)<br>COVID-19 mRNA vaccine (mutant strain), COVID-19 (booster vaccination, 5 to 11 aged children)    |  |  |  |
| DS-1471<br>Anti-CD147 antibody<br>Solid tumors   |  |   |  |   |  |  |  |

- Oncology
- Specialty medicine
- Vaccine
- Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
- ★ SAKIGAKE Designation (JP) ★ Orphan drug designation (designated in at least one country/region among JP, US and EU) ★ Rare Pediatric Disease Designation (US)
- ★ Fast Track Designation (US)

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, LBCL: large B cell lymphoma, PTCL: peripheral T-cell lymphoma